Olaplex Q3 Sales Dip 3.8%, Surpass Forecasts; CEO Highlights Progress on Transformation Goals

Core Insights - Olaplex's net sales decreased by 3.8% to $114.6 million in the third quarter compared to the same period last year, but this figure exceeded Wall Street's forecast of $111 million [1] - The company reported a net income of $11.1 million, down from $14.8 million in the same quarter of 2024, with diluted earnings per share at 2 cents [5] Sales Performance - Specialty retail sales fell by 13.5% to $36.9 million, while professional sales increased by 5.3% to $44.5 million, and direct-to-consumer sales decreased by 2.9% to $33.3 million [2] - Net sales in the U.S. decreased by 14.6%, whereas international sales increased by 7.1% [4] Strategic Initiatives - The CEO emphasized the importance of the professional business and the company's investment in a pro-first strategy, which is beginning to yield results [3] - The company is undergoing a transformation in retail, with ongoing improvements and tracking consumer responses to rebranding efforts [4] Acquisition - Olaplex announced the acquisition of Purvala Bioscience, marking its first acquisition in over 10 years, aimed at accessing new technologies for future growth [5][6]